BridgeMD
Compares treatment options for Onchocerciasis
Official title Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
ClinicalTrials.gov ID: NCT07145736
What this study is testing
What is Moxidectin?
Moxidectin is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for onchocerciasis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 5 and older. Healthy volunteers may be eligible.
You may be able to join if
- Male or female children and adults
- Residents in the villages selected for MDA treatment
You likely can't join if
- Arm 1 (ivermectin): children under the age of 5 and/or under 90 cm of height
- Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height/5 years of age and above).
- Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age
- Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)
- Know allergy to ivermectin or moxidectin
- Attending other clinical trials during the study
See the full eligibility criteria
- Male or female children and adults
- Residents in the villages selected for MDA treatment
- Arm 1 (ivermectin): children under the age of 5 and/or under 90 cm of height
- Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height/5 years of age and above).
- Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age
- Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)
- Know allergy to ivermectin or moxidectin
- Attending other clinical trials during the study
- Pregnant
- Arm 2 (moxidectin): Women planning to become pregnant in the 3 months post-treatment
- Refusal to receive one or both study drugs, i.e. participants in villages allocated to receive moxidectin who refuse to receive moxidectin will be given the option to receive ivermectin; if they refuse to receive both...
- Has an illness that makes them too sick or weak to get out of bed
- Currently hospitalized
The study team makes the final eligibility decision.
Where it's taking place
- Andulo, Bíe Province, Angola
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 5 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Andulo, Bíe Province, Angola. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.